Evestia Clinical Merges with Atlantic Research Group

ERT Merges with Bioclinica to Create Global Clinical Trial Endpoint Leader

December 10, 2020

Healthcare Services

ERT has merged with Bioclinica to create a global leader in clinical trial endpoint technology, combining Bioclinica's imaging and eClinical capabilities with ERT's expertise in eCOA, cardiac safety, respiratory and wearables. The transaction was completed in 2021 with Cinven (Bioclinica's owner) becoming a significant minority shareholder in ERT alongside Nordic Capital, Astorg and Novo Holdings A/S.

Everest Clinical Research (Arlington) Acquires August Research

November 7, 2023

Healthcare Services

Everest Clinical Research, a portfolio company of Arlington Capital Partners, has acquired European contract research organization August Research. The deal expands Everest's European footprint and clinical trial (CTS) and pharmacovigilance (PV) capabilities across 14 countries; August's founders will remain with the business. Financial terms were not disclosed.

CorEvitas Acquires Vestrum Health

July 22, 2021

Data & Analytics

CorEvitas, a provider of curated real-world evidence and a portfolio company of Audax Private Equity, has added Vestrum Health to its organization. The acquisition brings Vestrum’s retina-focused EHR data analytics and real-world evidence capabilities into CorEvitas’ registry and analytics platform to expand specialty EHR data and RWE services for retina practices and biopharmaceutical customers.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.

Arlington Capital Partners Makes Majority Investment in Everest Clinical Research Corporation

December 7, 2020

Healthcare Services

Washington, D.C.-based private equity firm Arlington Capital Partners has made a majority investment in Toronto-headquartered Everest Clinical Research Corporation, with Everest's founding shareholders and senior management rolling equity and continuing to lead the company. Everest is a full-service contract research organization (CRO) with ~300 employees across Toronto, Little Falls (NJ) and Shanghai; Arlington will support expansion of service lines, capabilities and headcount to drive growth.

Headlands Research Acquires Clinvest Research

May 4, 2023

Healthcare Services

Headlands Research, a multinational clinical trial site network, has acquired Clinvest Research, a Springfield, Missouri-based clinical research site that has conducted over 600 trials since 1996. The deal expands Headlands' chronic pain and endocrinology capabilities and increases participant access for trials in the United States.